Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
J Ethnopharmacol. 2021 Jun 28;274:114072. doi: 10.1016/j.jep.2021.114072. Epub 2021 Mar 26.
The ancient Chinese herbal formula Longdan Xiegan Tang (LXT, also called Gentiana Longdancao Decoction to Drain the Liver) treats insulin resistance- and inflammation-associated liver injuries in clinical practice.
To investigate the molecular mechanisms underlying LXT-elicited improvement of the liver injuries.
Male rats were co-treated with olanzapine (5 mg/kg) and LXT extract (50 and 500 mg/kg) for eight weeks. Blood parameters were determined enzymatically or by ELISA. Gene/protein expression was analyzed by Real-Time PCR, Western blot and/or immunohistochemistry.
LXT attenuated olanzapine-induced liver injury manifested by hyperactivities of plasma alanine aminotransferase and aspartate aminostransferase, hyperbilirubinemia and hypoalbuminemia. Furthermore, LXT improved hepatic insulin resistance that was indicated by hyperinsulinemia, the increased HOMA-IR index, and hepatic over-phosphorylation of Ser in insulin receptor substrate (IRS)1, Ser in IRS2, Tyr in phosphoinositide 3-kinase p85α and Ser in AKT at baseline. Mechanistically, LXT inhibited olanzapine-triggered hepatic over-phosphorylation of both IκB kinase (IKK)α/β and nuclear factor (NF)κB p65 proteins, and mRNA overexpression of tumor necrosis factor α, interleukin 6, interleukin 1β and CD68. More importantly, LXT restored the decreases in angiotensin-converting enzyme 2 (ACE2) protein level, and its downstream targets Ang (1-7) content and Mas receptor expression.
The present results demonstrate that LXT attenuates liver injury and hepatic insulin resistance by regulating the ACE2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats. Our findings provide a better understanding of LXT for treatment of insulin resistance- and inflammation-associated liver injuries.
古中药方龙胆泻肝汤(LXT,也称为龙胆草汤)在临床实践中治疗与胰岛素抵抗和炎症相关的肝损伤。
研究 LXT 改善肝损伤的分子机制。
雄性大鼠用奥氮平(5mg/kg)和 LXT 提取物(50 和 500mg/kg)共处理 8 周。通过酶法或 ELISA 测定血液参数。通过实时 PCR、Western blot 和/或免疫组织化学分析基因/蛋白表达。
LXT 减轻了奥氮平引起的肝损伤,表现为血浆丙氨酸氨基转移酶和天冬氨酸氨基转移酶活性升高、高胆红素血症和低白蛋白血症。此外,LXT 改善了肝胰岛素抵抗,表现为高胰岛素血症、HOMA-IR 指数增加以及胰岛素受体底物(IRS)1 上 Ser 的过度磷酸化、IRS2 上 Ser、磷酸肌醇 3-激酶 p85α 上 Tyr 和 AKT 上 Ser。从机制上讲,LXT 抑制了奥氮平触发的 IκB 激酶(IKK)α/β 和核因子(NF)κB p65 蛋白的过度磷酸化,以及肿瘤坏死因子α、白细胞介素 6、白细胞介素 1β 和 CD68 的 mRNA 过表达。更重要的是,LXT 恢复了血管紧张素转换酶 2(ACE2)蛋白水平及其下游靶标 Ang(1-7)含量和 Mas 受体表达的降低。
本研究结果表明,LXT 通过调节 ACE2/Ang(1-7)/Mas 轴介导的抗炎途径,减轻大鼠肝损伤和肝胰岛素抵抗。我们的发现为治疗与胰岛素抵抗和炎症相关的肝损伤提供了更好的理解。